Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PAB10054 - Provider product page
- Provider
- Abnova Corporation
- Proper citation
- Abnova Corporation Cat#PAB10054, RRID:AB_1708170
- Product name
- GSK3A (phospho S21) polyclonal antibody
- Antibody type
- Polyclonal
- Description
- Rabbit polyclonal antibody raised against synthetic phosphopeptide of GSK3A.
- Storage
- Store at 4°C. For long term storage store at -20°C.Aliquot to avoid repeated freezing and thawing.
Submitted references The primary defect in glycogen synthase activity is not based on increased glycogen synthase kinase-3alpha activity in diabetic myotubes.
Regulation of glycogen synthase kinase 3 in human platelets: a possible role in platelet function?
Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle.
Gaster M, Brusgaard K, Handberg A, Højlund K, Wojtaszewski JF, Beck-Nielsen H
Biochemical and biophysical research communications 2004 Jul 9;319(4):1235-40
Biochemical and biophysical research communications 2004 Jul 9;319(4):1235-40
Regulation of glycogen synthase kinase 3 in human platelets: a possible role in platelet function?
Barry FA, Graham GJ, Fry MJ, Gibbins JM
FEBS letters 2003 Oct 9;553(1-2):173-8
FEBS letters 2003 Oct 9;553(1-2):173-8
Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle.
Nikoulina SE, Ciaraldi TP, Mudaliar S, Carter L, Johnson K, Henry RR
Diabetes 2002 Jul;51(7):2190-8
Diabetes 2002 Jul;51(7):2190-8
No comments: Submit comment
Supportive validation
- Submitted by
- Abnova Corporation (provider)
- Main image
- Experimental details
- Western blot using GSK3A (phospho S21) polyclonal antibody (Cat # PAB10054) shows detection of a 52 KDa band corresponding to human GSK3A in various human derived 293T cell extracts.Cells were serum starved for 24 h.Lane 1 : control, Lane 2: treated with IGF-1 (100 ng/mL) for 20 min, Lane 3 : pre-treated with 10 uM PI3K inhibitor and treated with IGF-1 (100 ng/mL) for 20 min.Lane 1 shows some baseline GSK3A reactivity that is intensified upon stimulation (lane2) and diminished when aninhibitor is added (Lane 3).Approximately 20 ug of lysate was run on a SDS-PAGE and transferred onto nitrocel followed by reaction with a 1:1,000 dilution of anti-GSK3A antibody.Signal was detected using standard techniques.Personal communication, Angela Carter, Experimental Therapeutics, Ontario Cancer Inst, Toronto, Canada.
